IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

CAREDX, INC.

Plaintiff,

V.

C.A. No. 19-cv-662-CFC-CJB

NATERA, INC.,

Defendant.

PROPOSED JURY VERDICT FORM

INSTRUCTIONS

2

In answering the following questions and filling out this Verdict Form, you are to follow all of the instructions I have given you. Your answer to each question must be **unanimous**. Some of the questions contain legal terms that are explained in detail in the Jury Instructions. Please refer to the Jury Instructions if you are unsure about the meaning or usage of any legal term that appears in the questions below.

CAREDX QUESTIONS

Alleged Advertising Claim A

More sensitive and specific than current assessment tools across all types of rejection.

Introducing Prospera

Prospera is powered by highly optimized, proprietary cell-free DNA (cfDNA) technology. As part of your tool kit, Prospera assesses all types of kidney transplant rejection? with the greatest precision. ^{1,3}

- Simpler and less invasive than biopsy
- More sensitive and specific than current assessment tools across all types of rejection^{2,4,5}
- Up to 5x less variability than first-generation donor-derived cell-free DNA technology^{1,3}

JTX-7.2 (Brochure)

• More sensitive and specific than current assessment tools across all types of rejection:^{2,3,5} Serum creatinine tests are the current baseline screening standard, yet are not accurate enough for kidney transplant injury. Since then, first generation cell-free DNA technology has exhibited high variability. Prospera's published data shows better performance than both assessment methods.

JTX-5.3 (Website)

QUESTION NO. 1:

Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising for **Alleged Advertising Claim A**?

(for CareDx)

NO (for Natera)





CareDx Question No. 2 **Alleged Advertising Claim B** When comparing published clinical validation studies, Prospera The advertisement to the demonstrated better performance in correctly classifying patients right. with active rejection—including cell-mediated rejection.^{2,5} Other tests may incorrectly classify patients experiencing active rejection as normal (up to 1 out of 2 cases).5 Of 100 active rejection cases, the number of patients who would be missed, and told they are normal[‡] Prospera² 11/100 First-generation 41/100 Serum 48/100 dd-cfDNA5 creatinine² Sensitivity 89% Sensitivity 59% Sensitivity 52% JTX-7.3 (Brochure)

QUESTION NO. 2:

Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising for **Alleged Advertising Claim B**?

CareDx Question No. 3 Alleged Advertising Claim C The statements to the right. Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection Represents Successful Achievement of All 2018 Commercialization Milestones, on Path to 2019 Launch SAN CARLOS, Calif., Jan. 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced clinical validation study results published in the Journal of Clinical Medicine,1 demonstrating the highly accurate performance of its donor-derived cellfree DNA (dd-cfDNA) test for active allograft rejection in kidney transplant recipients, including higher sensitivity and nearly 18% higher area under the curve (AUC) than the competitive ddcfDNA assay.^{1,2} The study also reports the first accurate detection of T-cell mediated rejection (TCMR) and subclinical rejection. This marks the successful completion of all 2018 commercialization milestones, and is in line with the company's plan to secure Medicare coverage and commercially launch its test in 2019. JTX-12.1 (Press Release)

QUESTION NO. 3:


Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising for **Alleged Advertising Claim C**?

CareDx Question No. 4 Alleged Advertising Claim D The statements to the right. Natera Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay Core Technology Delivers Superior Analytical Performance, Underpins Outstanding Clinical Performance SAN CARLOS, Calif., Feb. 22, 2019 /PRNewswire/ -- Natera, Inc. results to be published online performance in detecting active allograft rejection (AR). In its recently published clinical validation study,4 Natera reported higher sensitivity (89% vs. 59%) and higher area under the curve (0.87 vs. 0.74) than the competing dd-cfDNA assay. 4.5 In that study, Natera also JTX-14.2 (Natera February 22, 2019 Press Release)


JTX 16 (Natera June 24, 2019 press release); JTX-17.2 (Natera December 19, 2019 press release);

QUESTION NO. 4:

Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising for **Alleged Advertising Claim D**?



Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising for **Alleged Advertising Claim E**?




QUESTION NO. 6:

Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising for **Alleged Advertising Claim F**?

	CareDx Question No. 7		10
Alleged Advertising Claim G			
The advertisement to the right.	Stronger test performance demonstrated		¥
		88 natera	CareDx*
	 Largest dd- cfDNA validation study (217 patients) 	217	107
	 Higher area under the curve; driven by superior clinical data 	0.87	0.74
	 First test to accurately detect TCMR (about 1/3 of all AR cases) 	10/10	3/11
	 First test to consistently detect subclinical rejection 	92%	N/A
	• 5x higher repeatability at 0.6% donor fraction (CV)	1.85	9.2
		JTX-21.11	! (CEOT Presentation)

QUESTION NO. 7:

Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising for **Alleged Advertising Claim G**?



QUESTION NO. 8:

Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising for **Alleged Advertising Claim H**?

12

Alleged Advertising Claim I

The advertisement to the right.

Now—catch ALL rejection types with a single blood draw

2

Prospera's unique ability to identify T cell-mediated rejection gives a more comprehensive view of your patient's rejection status.^{2,5}

Rejection Types	Prospera ²	First-generation dd-cfDNA ⁶
Antibody-mediated rejection (ABMR)	✓ Yes	✓ Yes
T cell-mediated rejection (TCMR) ≥ IA	✓ Yes	₩ No

JTX-7.3 (Brochure)

QUESTION NO. 9:

Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising for **Alleged Advertising Claim I**?

YES (for CareDx) NO (for Natera)





Alleged Advertising Claim J

The advertisement to the right.

Highly sensitive across a range of rejection types and patients



Broad distribution of rejection types

- Subclinical rejection
- T-cell mediated rejection IA/IB/IIB
- · Antibody-mediated rejection
- C4d-positive antibody-mediated rejection
- Acute rejection



Confidential. Not for further reproduction or use

Variety of ethnic & racial demographics

- Hispanic / Latino (n=50)
- Caucasian (n=74)
- African American (n=31)
- Asian (n=31)
- Age
 - Below 18 years of age (n=49)
 - 18 40 years of age (n=68)
 - Above 40 (n=100)



JTX-21.8 (CEOT Presentation) JTX23.8 (Billings Presentation)

QUESTION NO. 10:

Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising for **Alleged Advertising Claim J**?

YES (for CareDx)



NO (for Natera)



If you answered "Yes" to any one of Questions No. 1 - 10, you must answer Question No. 11.

If you answered "No" to all of Questions No. 1 - 10, you should skip Questions No. 11 - 16.

QUESTION NO. 11:

Did CareDx prove by a preponderance of the evidence that Natera intentionally and willfully engaged in false advertising?


YES (for CareDx) NO (for Natera)



If you answered "Yes" to any one of Questions No. 1 - 10, you must answer Question No. 12.

If you answered "No" to all of Questions No. 1 - 10, you should skip Questions No. 12 - 16.


QUESTION NO. 12: Did CareDx prove by a preponderance of the evidence that Natera is liable for false advertising under the Delaware Deceptive Trade Practices Act?



CareDx Question Nos. 13, 14 16 If you answered "Yes" to any one of Questions No. 1 - 10, you must answer Question No. 13. If you answered "No" to all of Question Nos. 1 - 10, you should skip Questions No. 13 - 16. YES NO **QUESTION NO. 13:** (for CareDx) (for Natera) Did CareDx prove by a preponderance of the evidence that Natera is liable for unfair competition? If you answered "Yes" to Question No. 13, you must answer Question No. 14. If you answered "No" to Question No. 13, you should skip Question Nos. 14 and 16. YES NO

QUESTION NO. 14:

Did CareDx prove by a preponderance of the evidence that Natera intentionally or recklessly engaged in unfair competition?



If you answered "Yes" to any one of Question Nos. 1 - 10, you must answer Question No. 15.

If you answered "No" to all of Question Nos. 1 - 10, you should skip Question Nos. 15 - 16.

QUESTION NO. 15:

What amount, if any, is CareDx entitled to recover as actual damages attributable to Natera's false advertising and/or unfair competition?

Answer: \$ 21,200,000 (21,2m)

If you answered "Yes" to Question No. 14 and you awarded compensatory damages in response to Question No. 15, you must answer Question No. 16.

If you answered "No" to Question No. 14 or you awarded no compensatory damages in response to Question No. 15, you should skip Question No. 16.

QUESTION NO. 16: What amount of punitive damages, if any, do you award CareDx for Natera's unfair competition?

Answer: \$ 23.7 million

NATERA QUESTIONS

Alleged Advertising Claim

1. The advertisement to the right.

DTX135.00002 Method 1: Rigorous Scientific Method1 vs. Lack of Scientific Rigor2

	CareDx 100% Transplant Focused Applying Rigorous Scientific Approach
Scientific Design	Multi-Center Prospective
Number of Centers	14
Patient Selection ^{3,4}	No eGFR selection bias
AUC ⁵	0.74
Definition of Active Rejection	Banff criteria used ¹ , accepted in kidney transplant community
Sensitivity	59%
Specificity	85%
NPV	84%
PPV	60%
Journal ^{7,8}	JASN

Method 2:

Other Test: Non-Transplant Focused	Applying Other Test Method to DART Data
Retrospective Single-Center	Multi-Center Prospective
1	14
Selection bias illustrated by eGFR	Selection bias illustrated by eGFR
0.87	1.0
Non-Banff definition used to segment patients ⁶	Non-Banff definition used to segment patients ⁶
89%	100%
73%	100%
95%	100%
53%	100%
JCM	



© 2019 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.

- including 384 patients and full Banff 2013 criteria is reflective of real incidence and accurate analysis
- 2. Competitor study is a limited retrospective single center analysis
- 3. Sample selection bias makes analysis inapplicable to real world patients
- 1. Bloom R. JASN publication-Multi-Center (14) 4. eGFR pattern between groups demonstrate selection bias
 - 5. AUC's cannot be compared unless same method has been used
 - 6. Banff 2017 criteria used was incomplete, introducing bias
 - 7. Journal of the American Society of Nephrology
 - 8. Journal of Clinical Medicine

NATERA QUESTION NO. 1:

Did Natera prove by a preponderance of the evidence that CareDx is liable for false advertising for Alleged Advertising Claim 1?

YES (for Natera)







21

Alleged Advertising Claim

2. " 'While CareDx was not involved in this head-to-head comparison, we are not surprised by the results as AlloSure was developed for transplant specific needs, including accurate testing at low cfDNA levels and fast turnaround times,' said Sham Dholakia, SVP of Medical Affairs at CareDx."

DTX144

Press Releases

Jun 22, 2020

<< Back

New Kidney360 Publication Highlights CareDx's AlloSure is Differentiated as the dd-cfDNA Test of Choice

Head to head data shows that not all dd-cfDNA is the same

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today that the journal of the American Society of Nephrology, *Kidney360*, published a study evaluating AlloSure simultaneously with a different donor-derived cell-free DNA (dd-cfDNA) monitoring tool for allograft rejection.

This study evaluated 76 kidney transplant patients and surveilled post-transplant kidney rejection utilizing AlloSure and one other dd-cfDNA monitoring tool. Overall, the study found that while there were no significant differences between the diagnostic test characteristics, AlloSure was proven to be more accurate in clinical interpretation and significantly faster in delivering patient results. The study evaluated dd-cfDNA samples and concluded that AlloSure had a significantly superior turnaround time with 75% of the results returned at least one day earlier.

"Our study findings further validated the published data on AlloSure, a transplant-focused analytical tool for allograft rejection using donor-derived cell-free DNA," said Joseph K. Melancon, MD, The George Washington University Hospital. "Although dd-cfDNA tests are similar, they are not the same."

"While CareDx was not involved in this head-to-head comparison, we are not surprised by the results as AlloSure was developed for transplant specific needs, including accurate testing at low cfDNA levels and fast turnaround times," said Sham Dholakia, SVP of Medical Affairs at CareDx.

NATERA QUESTION NO. 2:

Did Natera prove by a preponderance of the evidence that CareDx is liable for false advertising for **Alleged Advertising Claim 2**?

YES (for Natera) NO

X



Natera Question No. 3 22 Alleged DTX085.00001, .00005 **Advertising Claims** 3. "I declare no Kidney360 Publish Ahead of Print, published on June 19, 2020 as doi:10.34067/KID.0003512020 conflict of interest and performed this study independent of Donor Derived Cell Free DNA: is it all the same? any company Joseph K. Melancon¹ involvement." ¹Department of Surgery, The George Washington University Hospital, Washington, D.C., U.S.A. and Corresponding Author: Joseph K. Melancon, MD 2131 K Street NW, Washington, D.C., 20037, U.S.A. "No external funding Email address: jmelancon@mfa.gwu.edu was received." Disclosures J Melancon is on the speaker's bureau of Natera and CareDx. I declare no conflict of interest and performed this study independent of any company involvement. Acknowledgements/Funding No external funding was received. **Author Contributions** J Melancon: Conceptualization; Data curation; Formal analysis; Investigation; Writing - original draft; Writing - review and editing


NATERA QUESTION NO. 3:

Did Natera prove by a preponderance of the evidence that CareDx is liable for false advertising for **Alleged Advertising Claims 3**?

YES NO
(for Natera) (for CareDx)

Alleged Advertising Claim

4. "Allosure can accurately determine active rejection, enabling better management of your kidney transplant patients."



- *Active Rejection = acute/active ABMR; chronic, active ABMR; and TCMR IA and greater
- ¹ Prevalence of rejection within the first year post-transplant
- "Prevalence of ABMR in DSA positive patients

NATERA QUESTION NO. 4:

Did Natera prove by a preponderance of the evidence that CareDx is liable for false advertising for **Alleged Advertising Claim 4**?

YES (for Natera)



NO (for CareDx)



24

Alleged Advertising Claim


5. "95% NPV for Active Rejection"

DTX125.00004

AlloSure performance characteristics

96% of AlloSure results for samples from DART healthy stable recipients are below the 1% threshold **50%** of AlloSure results for samples from DART healthy stable recipients are below 0.21%

ALLOSURE CAN RULE OUT REJECTION



NATERA QUESTION NO. 5:

Did Natera prove by a preponderance of the evidence that CareDx is liable for false advertising for **Alleged Advertising Claim 5**?

YES (for Natera)

NO (for CareDx)





^{*}Active Rejection = acute/active ABMR; chronic, active ABMR; and TCMR IA and greater

[†] Prevalence of rejection within the first year post-transplant

Prevalence of ABMR in DSA positive patients



25

Alleged Advertising Claim

6. "95% NPV for Active Rejection"


DTX138.00010

AlloSure: A Surveillance Test To Detect Graft Injury And Determine Rejection

WITH A HIGH NPV, ALLOSURE CAN CONFIDENTLY RULE OUT INJURY & REJECTION

96% of AlloSure results from DART healthy stable recipients are below the 1% threshold
50% of AlloSure results from DART healthy stable recipients are below 0.21%

ALLOSURE CAN RULE OUT REJECTION



*Active Rejection = acute/active ABMR; chronic, active ABMR; and TCMR IA and greater † Prevalence of rejection within the first year post-transplant ~ Prevalence of ABMR in DSA positive patients Bloom RD et al. J Am Soc Nephrol. 2017;28(7): 2221-2232
 Jordan et al. J Am Soc Nephrol 28:Suppl, 2017

NATERA QUESTION NO. 6:


Did Natera prove by a preponderance of the evidence that CareDx is liable for false advertising for **Alleged Advertising Claim 6**?

YES (for Natera)

NO (for CareDx)



Natera Question No. 7 26 Alleged DTX128.004, .005 **Advertising Claim 7.** "Allosure < 0.21% REASSURANCE WITH A LOW ALLOSURE SCORE has 95% NPV for Active Rejection" Distribution of dd-cfDNA ALLOSURE < 0.21% Number of test results in reference population from DART study1 has 95% NPV for Active Rejection*4 0.21% is the median from DART healthy stable recipients dd-cfDNA (%) 1. Jordan SC et al. Transplant Direct 2018; 4:e379 3. Stites E et al. Am J Transplant 2020 Feb; doi: 10.1111/ajt.15822 [Epub ahead of print] 2. Bloom RD et al. J Am Soc Nephrol 2017; 28:2221-2232 4. Bromberg JS et al. J Appl Lab Med 2017; 2:309-321 YES NO NATERA QUESTION NO. 7: (for Natera) (for CareDx) Did Natera prove by a preponderance of the evidence that CareDx is liable for false advertising for Alleged Advertising Claim 7?



If you answered "Yes" to any one of Natera Questions No. 1 - 8, you must answer Natera Question No. 9.

If you answered "No" to all of Natera Questions No. 1 - 8, you should skip Natera Questions No. 9 - 12.

NATERA QUESTION NO. 9:

Did Natera prove by a preponderance of the evidence that CareDx is liable for false advertising under the Delaware Deceptive Trade Practices Act?

YES (for Natera)

NO (for CareDx)

28

X

If you answered "Yes" to any one of Natera Questions No. 1 - 8, you must answer Natera Question No. 10.

If you answered "No" to all of Natera Questions No. 1 - 8, you should skip Natera Question No. 10.

NATERA QUESTION NO. 10:

Did Natera prove by a preponderance of the evidence that CareDx intentionally and willfully engaged in false advertising?

YES (for Natera) **NO** (for CareDx)

29



X


Natera Questions No. 11, 12

If you answered "Yes" to any one of Natera Questions No. 1 - 8, you must answer Natera Question No. 11.

If you answered "No" to all of Natera Questions No. 1 - 8, you should skip Natera Questions No. 11 - 12.

NATERA QUESTION NO. 11:

Did Natera prove by a preponderance of the evidence that CareDx is liable for unfair competition?




If you answered "Yes" to Natera Question No. 11, you must answer Natera Question No. 12.

If you answered "No" to Natera Question No. 11, you should skip Natera Question No. 12.

NATERA QUESTION NO. 12:

Did Natera prove by a preponderance of the evidence that CareDx intentionally or recklessly engaged in unfair competition?



You have reached the end of the verdict form. Review the completed form to ensure that it accurately reflects your **unanimous** determinations. The Foreperson should then sign and date the verdict form in the space below and notify the Court Security Officer that you have reached a verdict. The Foreperson should place the completed verdict form in the envelope provided to you and retain possession of it until the jury returns to the courtroom.

retarns to the courtroom.	
Dated: 3/14/2022	Foreperson